Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees118
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions
What is Kaleido Biosciences' stock symbol?
Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."
How were Kaleido Biosciences' earnings last quarter?
Kaleido Biosciences Inc (NASDAQ:KLDO) released its earnings results on Thursday, August, 1st. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.09. View Kaleido Biosciences' Earnings History.
When is Kaleido Biosciences' next earnings date?
What price target have analysts set for KLDO?
5 Wall Street analysts have issued 12-month price objectives for Kaleido Biosciences' shares. Their predictions range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.70 in the next twelve months. This suggests a possible upside of 234.0% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.
What is the consensus analysts' recommendation for Kaleido Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.
Has Kaleido Biosciences been receiving favorable news coverage?
News articles about KLDO stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kaleido Biosciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Kaleido Biosciences.
Who are some of Kaleido Biosciences' key competitors?
Some companies that are related to Kaleido Biosciences include Axsome Therapeutics (AXSM), ZIOPHARM Oncology (ZIOP), Cortexyme (CRTX), Krystal Biotech (KRYS), AVITA MED LTD/S (RCEL), Revance Therapeutics (RVNC), Global Cord Blood (CO), Mesoblast (MESO), Cerus (CERS), Heska (HSKA), Homology Medicines (FIXX), Vectura Group (VEC), NextCure (NXTC), Advanz Pharma (CXRXF) and Integral Diagnostics (IDX).
What other stocks do shareholders of Kaleido Biosciences own?
Who are Kaleido Biosciences' key executives?
Kaleido Biosciences' management team includes the folowing people:
- Mr. Michael W. Bonney, Exec. Chair (Age 61)
- Ms. Alison Lawton, CEO, Pres & Director (Age 58)
- Dr. Noubar B. Afeyan Ph.D., Co-Founder & Director (Age 56)
- Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 38)
- Mr. Joshua T. Brumm, COO & CFO (Age 41)
When did Kaleido Biosciences IPO?
(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
When did Kaleido Biosciences' lock-up period expire?
Kaleido Biosciences' lock-up period expired on Tuesday, August 27th. Kaleido Biosciences had issued 5,000,000 shares in its initial public offering on February 28th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.
How do I buy shares of Kaleido Biosciences?
Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kaleido Biosciences' stock price today?
One share of KLDO stock can currently be purchased for approximately $5.30.
How big of a company is Kaleido Biosciences?
MarketBeat Community Rating for Kaleido Biosciences (NASDAQ KLDO)
MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote "Outperform" if you believe KLDO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.
